RSS   Newsletter   Contact   Advertise with us

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 billion

Christian Fernsby ▼ | August 26, 2019
Amgen said on it would buy Celgene’s psoriasis drug Otezla for $13.4 billion in cash.
Amgen
Acquisition   This is clearing the way for Bristol-Myers Squibb to go ahead
This is clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Topics: Amgen Celgene

The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits.

Bristol-Myers Squibb Co in June offered to sell Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.


 

MORE INSIDE POST